Any Place for Immunohistochemistry Within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2018 Mar 14

PMID 29534030

Citations 9

Authors

Veronique Hofman

Sandra Lassalle

Coraline Bence

Elodie Long-Mira

Sacha Nahon-Esteve

Simon Heeke

Virginie Lespinet-Fabre

Catherine Butori

Marius Ilie

Paul Hofman

Affiliations

Soon will be listed here.

Abstract

The identification of certain genomic alterations (, , , ) or immunological markers (PD-L1) in tissues or cells has led to targeted treatment for patients presenting with late stage or metastatic lung cancer. These biomarkers can be detected by immunohistochemistry (IHC) and/or by molecular biology (MB) techniques. These approaches are often complementary but depending on, the quantity and quality of the biological material, the urgency to get the results, the access to technological platforms, the financial resources and the expertise of the team, the choice of the approach can be questioned. The possibility of detecting simultaneously several molecular targets, and of analyzing the degree of tumor mutation burden and of the micro-satellite instability, as well as the recent requirement to quantify the expression of PD-L1 in tumor cells, has led to case by case development of algorithms and international recommendations, which depend on the quality and quantity of biological samples. This review will highlight the different predictive biomarkers detected by IHC for treatment of lung cancer as well as the present advantages and limitations of this approach. A number of perspectives will be considered.

Citing Articles

Current challenges and practical aspects of molecular pathology for non-small cell lung cancers.

Hofman P, Berezowska S, Kazdal D, Mograbi B, Ilie M, Stenzinger A Virchows Arch. 2023; 484(2):233-246.

PMID: 37801103 PMC: 10948551. DOI: 10.1007/s00428-023-03651-1.

A Real-World Experience from a Single Center (LPCE, Nice, France) Highlights the Urgent Need to Abandon Immunohistochemistry for ROS1 Rearrangement Screening of Advanced Non-Squamous Non-Small Cell Lung Cancer.

Hofman V, Goffinet S, Bontoux C, Long-Mira E, Lassalle S, Ilie M J Pers Med. 2023; 13(5).

PMID: 37240980 PMC: 10222775. DOI: 10.3390/jpm13050810.

Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report.

Zhou H, Xu B, Xu J, Zhu G, Guo Y Front Oncol. 2021; 11:670907.

PMID: 34168990 PMC: 8217641. DOI: 10.3389/fonc.2021.670907.

Identification of lncRNA biomarkers for lung cancer through integrative cross-platform data analyses.

Zhao T, Khadka V, Deng Y Aging (Albany NY). 2020; 12(14):14506-14527.

PMID: 32675385 PMC: 7425463. DOI: 10.18632/aging.103496.

The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients.

Hofman P J Thorac Dis. 2019; 11(Suppl 1):S57-S64.

PMID: 30775028 PMC: 6353749. DOI: 10.21037/jtd.2018.11.85.

References

Ng Kee Kwong F, Laggner U, McKinney O, Croud J, Rice A, Nicholson A . Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas. Histopathology. 2018; 72(6):1024-1032. DOI: 10.1111/his.13466. View

Ilie M, Hofman V, Dietel M, Soria J, Hofman P . Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 2016; 468(5):511-25. DOI: 10.1007/s00428-016-1910-4. View

Park S, Koh J, Kim D, Kim M, Keam B, Kim T . MET amplification, protein expression, and mutations in pulmonary adenocarcinoma. Lung Cancer. 2016; 90(3):381-7. DOI: 10.1016/j.lungcan.2015.10.022. View

Lewis C, McQuaid S, Hamilton P, Salto-Tellez M, McArt D, James J . Building a 'Repository of Science': The importance of integrating biobanks within molecular pathology programmes. Eur J Cancer. 2016; 67:191-199. DOI: 10.1016/j.ejca.2016.08.009. View

Rossi G, Jocolle G, Conti A, Tiseo M, Marino F, Donati G . Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives. Lung Cancer (Auckl). 2017; 8:45-55. PMC: 5508815. DOI: 10.2147/LCTT.S120172. View

Luk P, Yu B, Ng C, Mercorella B, Selinger C, Lum T . BRAF mutations in non-small cell lung cancer. Transl Lung Cancer Res. 2015; 4(2):142-8. PMC: 4384219. DOI: 10.3978/j.issn.2218-6751.2014.08.08. View

Conde E, Hernandez S, Prieto M, Martinez R, Lopez-Rios F . Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas. Expert Rev Mol Diagn. 2016; 16(6):707-13. DOI: 10.1586/14737159.2016.1172963. View

Long E, Ilie M, Hofman V, Lassalle S, Butori C, Alsubaie S . [Role of the surgical pathologist for tissue management in oncology]. Bull Cancer. 2013; 100(9):837-45. DOI: 10.1684/bdc.2013.1803. View

Ibrahim M, Parry S, Wilkinson D, Bilbe N, Allen D, Forrest S . ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment Regimen. J Thorac Oncol. 2016; 11(12):2241-2247. DOI: 10.1016/j.jtho.2016.07.012. View

10.

Ritterhouse L, Barletta J . BRAF V600E mutation-specific antibody: A review. Semin Diagn Pathol. 2015; 32(5):400-8. DOI: 10.1053/j.semdp.2015.02.010. View

11.

Labarca G, Aravena C, Ortega F, Arenas A, Majid A, Folch E . Minimally Invasive Methods for Staging in Lung Cancer: Systematic Review and Meta-Analysis. Pulm Med. 2016; 2016:1024709. PMC: 5081694. DOI: 10.1155/2016/1024709. View

12.

Hofman V, Ilie M, Gavric-Tanga V, Lespinet V, Mari M, Lassalle S . [Role of the surgical pathology laboratory in the pre-analytical approach of molecular biology techniques]. Ann Pathol. 2010; 30(2):85-93. DOI: 10.1016/j.annpat.2010.03.003. View

13.

Pierceall W, Olaussen K, Rousseau V, Brambilla E, Sprott K, Andre F . Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol. 2012; 23(9):2245-2252. DOI: 10.1093/annonc/mdr624. View

14.

Bussolati G, Annaratone L, Maletta F . The pre-analytical phase in surgical pathology. Recent Results Cancer Res. 2015; 199:1-13. DOI: 10.1007/978-3-319-13957-9_1. View

15.

Wen Y, Brogi E, Hasanovic A, Ladanyi M, Soslow R, Chitale D . Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma. Mod Pathol. 2013; 26(9):1197-203. PMC: 4159955. DOI: 10.1038/modpathol.2013.53. View

16.

Yu H, Boyle T, Zhou C, Rimm D, Hirsch F . PD-L1 Expression in Lung Cancer. J Thorac Oncol. 2016; 11(7):964-75. PMC: 5353357. DOI: 10.1016/j.jtho.2016.04.014. View

17.

Mascaux C, Tomasini P, Greillier L, Barlesi F . Personalised medicine for nonsmall cell lung cancer. Eur Respir Rev. 2017; 26(146). PMC: 9489039. DOI: 10.1183/16000617.0066-2017. View

18.

Seo A, Park T, Jin Y, Sun P, Kim H, Chang H . Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry. Lung Cancer. 2014; 83(3):316-23. DOI: 10.1016/j.lungcan.2013.12.008. View

19.

Bubendorf L, Lantuejoul S, de Langen A, Thunnissen E . Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza. Eur Respir Rev. 2017; 26(144). PMC: 9488516. DOI: 10.1183/16000617.0007-2017. View

20.

Ilie M, Butori C, Lassalle S, Heeke S, Piton N, Sabourin J . Optimization of mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer. Oncotarget. 2017; 8(61):103055-103062. PMC: 5732710. DOI: 10.18632/oncotarget.21476. View